Clinical TrialAug 6, 2026, 12:02 PM
MiNK Therapeutics' agenT-797 Shows Positive Phase 2 Results
AI Summary
MiNK Therapeutics announced initial positive observations from its ongoing Phase 2 study of agenT-797 in patients with severe hypoxemic pneumonia. Patients treated with agenT-797 were alive and afebrile at Day 28, showing improved oxygenation, infection control, and removal from life support. Biological analyses indicated immune recovery and tissue repair, with no major serious adverse events reported. The company highlighted the rapid deployment of its off-the-shelf therapy in austere environments, with enrollment continuing and further data expected in early 2027.
Key Highlights
- First patients treated with agenT-797 were alive and afebrile at endpoint Day 28.
- Patients showed improved oxygenation, infection control, and removal from ventilator/vasopressor support.
- Analysis of blood and lung fluid indicated immune recovery, tissue repair, and pulmonary recovery.
- No major serious adverse events attributed to agenT-797 were reported in these first patients.
- Enrollment continues in Lviv, Ukraine, with U.S. sites opening for the Phase 2 study.
- Additional data from the C-1300-02 trial are expected in early 2027.
- agenT-797 is an off-the-shelf therapy, enabling rapid dosing without patient-specific manufacturing or HLA matching.
Price Impact
More from INKT